Seven Days In March: NDA-BLA and ANDA Approval Output Diverged As Coronavirus Teleworking Began

 
• By Derrick Gingery

New drug approvals dropped, likely because of a new focus on COVID-19 treatments, while generic drug approvals increased.

Machinery cogwheels, industry concept
The coronavirus outbreak forced changes to FDA workflow and priorities, which may have affected NDA-BLA approval output. • Source: Shutterstock

More from Product Reviews

More from Pink Sheet